Skip to main content
. Author manuscript; available in PMC: 2009 Feb 13.
Published in final edited form as: Vaccine. 2008 Jan 4;26(7):882–890. doi: 10.1016/j.vaccine.2007.12.015

Table 3.

Immunologic response of volunteers following a second 103 PFU dose of the chimeric LGT/DEN4 vaccine candidate.

Volunteer ID# Code
Serum neutralizing antibody titer on indicated day againsta:
TBEV/DEN4Δ30
LGT
1-st dose 2-nd dose 0 28 42 180 0 28 42 180
19 Placebo Placebo < 5 < 5 < 5 < 5 < 5 < 5 < 5 < 5
26 Placebo Placebo < 5 < 5 < 5 < 5 < 5 < 5 < 5 < 5
12 Placebo Vaccine < 5 < 5 < 5 < 5 < 5 < 5 < 5 < 5
16 Placebo Vaccine < 5 < 5 < 5 < 5 < 5 < 5 < 5 < 5
25 Placebo Vaccine < 5 298 568 68 < 5 1008 649 147
01 Vaccine Vaccine < 5 6 5 < 5 19 39 22 28
03 Vaccine Vaccine < 5 < 5 < 5 < 5 < 5 17 11 5
04 Vaccine Vaccine 38 36 37 36 157 187 164 83
05 Vaccine Vaccine 39 51 31 28 289 446 381 86
08 Vaccine Vaccine 14 39 33 28 28 100 88 26
10 Vaccine Vaccine < 5 < 5 < 5 < 5 < 5 6 5 7
11 Vaccine Vaccine 8 9 5 37 34 48 52 56
13 Vaccine Vaccine < 5 < 5 < 5 < 5 14 29 31 20
17 Vaccine Vaccine < 5 < 5 < 5 < 5 < 5 58 92 30
18 Vaccine Vaccine < 5 < 5 < 5 < 5 11 21 14 13
20 Vaccine Vaccine < 5 < 5 < 5 < 5 < 5 16 14 < 5
22 Vaccine Vaccine < 5 < 5 < 5 < 5 10 36 44 11
23 Vaccine Vaccine 35 30 76 10 55 85 67 49
27 Vaccine Vaccine < 5 < 5 5 < 5 5 11 12 7
28 Vaccine Vaccine < 5 7 < 5 < 5 < 5 50 19 < 5
29 Vaccine Vaccine 17 11 9 14 127 163 164 80
GMTb: 8 9 8 8 17 45 38 19
Seropositive: 6/16 8/16 8/16 6/16 11/16 16/16 16/16 14/16
38% 50% 50% 38% 69% 100% 100% 88%
Seroconversion: 0/16 0/16 1/16 2/16 2/16 1/16
0% 0% 6% 13% 13% 6%
1/16 = 6% 3/16 = 19%
a

Plaque reduction (60%) neutralizing antibody titers (reciprocal) were determined against wild-type LGT TP21 strain or chimeric TBEV/DEN4Δ30 virus as indicated.

b

GMT, geometric mean titers (reciprocal) are calculated for 16 vaccine recipients and does not include 3 volunteers who received placebo in primary inoculation and vaccine in second inoculation. Seroconversion (indicated by shading) is defined as a ≥4-fold rise in serum neutralizing antibody titer on day 28, 42, or 180 after booster vaccination, compared with a titer observed in serum of volunteers prior to receive a booster dose of LGT/DEN4 vaccine.